TRI Strategic Plan 2019 - 2021

TRI has four shareholder organisations: Queensland Health Princess Alexandra Hospital (PAH), Mater Medical Research Institute (MMRI), The University of Queensland (UQ) and the Queensland University of Technology (QUT). The TRI concept was funded and mandated by the Australian Government and Queensland Government with support from Atlantic Philanthropies, QUT and UQ.

OUR VISION: TRI will be a global leader in the effective translation of research and innovation into improved healthcare and increased income and jobs for Australia.


To improve health outcomes from early innovative translational research and effective clinical interface. In doing so be further recognised as a global leader. To deliver improved healthcare, integration with industry and increased income for Australia from its innovations. Deliver a well trained workforce to lead Australia going forward able to deliver healthcare outcomes in a changing environment.

Goal 1– Improve Healthcare by ensuring that early innovative translational research is successfully implemented in clinical practice. 


  1. Expand the interface between clinicians and scientists that has successfully led to outcomes for important clinical questions.
  2. Continue to insert research nurses and program managers into programs that allow the clinicians clear and defined input while in full time clinical roles. 
  3. Work with the State Government to expand the presence of industry onsite at TRI, to include startups and big industry.
  4. Make available health economic evaluations in order to generate commercial and government interest and support.
  5. In collaboration with shareholder organizations, ensure that TRI has a computing capability that allows:
    - the advantages of the digital hospital to be to be integrated with innovative research and development programs;

    - a cyber-protected data transfer system to facilitate maximum interface for TRI programs to include Metro North,  the Mater and other Hospitals around Australia that do not yet have the digital hospital capacity.

Goal 2 – Be recognised globally, nationally and in Queensland as a leader in translation of innovation.


  1. Continue to develop a significant international and national public profile for TRI by appropriate benchmarking.
  2. Work closely with the University DVCRs, Hospital CEOs and State Government Directors General to consider new initiatives.
  3. Ensure that TRI leadership in specific translational disciplines (to include but not limited toimmunotherapy, diagnostic genomics, diagnostic imaging and dermoscopy) are documented and clearly visible to current and potential academic, commercial and government partners
  4. Assist the start-ups and major industry based at TRI to achieve their goals.
  5. Form strong collaborations with internationally-recognized institutions to both learn from and jointly deliver product and/or improved healthcare outcomes. In doing so provide a means of benchmarking TRI internationally.

Goal 3 – Train future leaders in translation of innovation, in particular how to interface with industry and to think globally.


  1. Maintain and enhance the SPARQ-Ed program for inspiring primary and secondary school children to consider a career in biomedical research.
  2. Embed a new Stanford Spark program at TRI and in doing so assist the new innovation programs to learn from, and work with, industry and business.
  3. Train future leaders in how to translate and interface with industry through:

    - The translational pipeline used to describe and simplify the complex processes oftranslating a wide variety of scientific and clinical research

    - The annual Brisbane wide TRI Translational Symposium organised by a TRI-wide Committeeof PhD students

    - The TRI Science Business Inspiration Series (SBIS) organised by a committee of early career researchers and clinicians eager to build their business knowledge and connections.

Goal 4 – Develop a Strong Clinical Trials Capability and Network.  


  1. Ensure that both [email protected] and [email protected] translators have access to and necessary support for clinical trials.
  2. Ensure that the startups in TRI have access to the clinical trials facility.
  3. Deliver a new clinical trials capability, in the imaging space and in other disciplines, to partner with world class sites.
  4. Partner with internationally recognized sites to undertake clinical trials and in doing so fulfill the requirements for US FDA approved trials.

Goal 5 – Use the strong business and clinical trial capabilities in the TRI ELT and partner organisations to participate in Federal and State Government initiatives.


  1. Be cognisant of the operational and business challenges the innovation funding opportunities bring.
  2. Ensure that both TRI and partner translators have the business and marketing capability to support business driven opportunities.
  3. Form strong collaborations locally, nationally and internationally to deliver on State and Federal Government initiatives as well as business opportunities.
  4. Provide strong support for the new programs under development at TRI that include, but are not limited to, the role of the microbiome in health and disease; tissue engineering for complex reconstructive surgery; preventing acute pain and PTSD becoming chronic, supported by aworld class clinical trials capability.
  5. Develop international ties and new collaborations in the area of clinical trials

vision & VAlues:

TRI’s vision is to “create a world with better health outcomes achieved through translational research.” TRI will be recognised as a global leader in effective translation of research and innovation into improved healthcare. The TRI vision is achieved through a values driven corporate culture focused on collaboration to achieve excellence.

We LIKE Collaboration


Our actions will shape a healthier world


We do the right thing. Always


Through sharing, we empower innovation


We strive for exceptional outcomes 


Together we’re better